Oncolytics Biotech Stock Price, News & Analysis (TSE:ONC)

C$0.73 -0.01 (-1.35 %)
(As of 11/22/2017 05:49 AM ET)
Previous CloseC$0.74
Today's RangeC$0.73 - C$0.75
52-Week RangeC$0.19 - C$1.13
Volume249,403 shs
Average Volume276,979 shs
Market CapitalizationC$106.93 million
P/E RatioN/A
Dividend YieldN/A
Beta0.98

About Oncolytics Biotech (TSE:ONC)

Oncolytics Biotech logoOncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.


Industry, Sector and Symbol:
Profitability:
  • Trailing EPS: C($0.13)
  • Return on Equity: -161.95%
  • Return on Assets: -123.71%
Misc:
  • Outstanding Shares: 139,426,000
 

Frequently Asked Questions for Oncolytics Biotech (TSE:ONC)

What is Oncolytics Biotech's stock symbol?

Oncolytics Biotech trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ONC."

When will Oncolytics Biotech make its next earnings announcement?

Oncolytics Biotech is scheduled to release their next quarterly earnings announcement on Friday, March, 9th 2018. View Earnings Estimates for Oncolytics Biotech.

Where is Oncolytics Biotech's stock going? Where will Oncolytics Biotech's stock price be in 2017?

2 analysts have issued 1 year price objectives for Oncolytics Biotech's stock. Their forecasts range from C$1.50 to C$1.50. On average, they anticipate Oncolytics Biotech's stock price to reach C$1.50 in the next year. View Analyst Ratings for Oncolytics Biotech.

Who are some of Oncolytics Biotech's key competitors?

Who are Oncolytics Biotech's key executives?

Oncolytics Biotech's management team includes the folowing people:

  • Wayne F. Pisano, Chairman of the Board
  • Matthew C. Coffey Ph.D., President, Chief Executive Officer, Chief Operating Officer, Director
  • Kirk J. Look, Chief Financial Officer
  • George M. Gill M.D., Senior Vice President - Regulatory Affairs & Chief Safety Officer
  • Mary Ann Dillahunty J.D., Vice President - Intellectual Property
  • Andres A. Gutierrez, Chief Medical Officer
  • Alan J. Tuchman M.D., Chief Neuro Oncology Research Officer (Age 69)
  • Deborah Brown, Director
  • Angela Frances Holtham, Director
  • Edwin Levy Ph.D., Director

How do I buy Oncolytics Biotech stock?

Shares of Oncolytics Biotech and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Oncolytics Biotech's stock price today?

One share of Oncolytics Biotech stock can currently be purchased for approximately C$0.73.

How big of a company is Oncolytics Biotech?

Oncolytics Biotech has a market capitalization of C$106.93 million.

How can I contact Oncolytics Biotech?

Oncolytics Biotech's mailing address is 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada. The company can be reached via phone at +1-403-6707380.


MarketBeat Community Rating for Oncolytics Biotech (TSE ONC)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  68 (Vote Outperform)
Underperform Votes:  33 (Vote Underperform)
Total Votes:  101
MarketBeat's community ratings are surveys of what our community members think about Oncolytics Biotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Oncolytics Biotech (TSE:ONC)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: C$1.50

Consensus Price Target History for Oncolytics Biotech (TSE:ONC)

Price Target History for Oncolytics Biotech (TSE:ONC)

Analysts' Ratings History for Oncolytics Biotech (TSE:ONC)

Show:
DateFirmActionRatingPrice TargetDetails
4/13/2017BMO Capital MarketsBoost Price TargetOutperformC$1.00 -> C$1.50View Rating Details
4/13/2017Royal Bank Of CanadaBoost Price TargetOutperformC$1.00 -> C$1.50View Rating Details
(Data available from 11/22/2015 forward)

Earnings

Earnings History and Estimates Chart for Oncolytics Biotech (TSE:ONC)

Earnings by Quarter for Oncolytics Biotech (TSE:ONC)

Earnings History by Quarter for Oncolytics Biotech (TSE ONC)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/9/2018        
8/7/2014Q2 14C($0.07)C($0.05)ViewN/AView Earnings Details
11/7/2013Q3 13C($0.07)C($0.07)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Oncolytics Biotech (TSE:ONC)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Oncolytics Biotech (TSE:ONC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Oncolytics Biotech (TSE ONC)

Insider Trades by Quarter for Oncolytics Biotech (TSE:ONC)

Insider Trades by Quarter for Oncolytics Biotech (TSE ONC)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/26/2015Angela Frances HolthamDirectorBuy5,000C$0.89C$4,450.00
5/12/2015Wayne PisanoDirectorBuy20,000C$0.76C$15,150.00
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Oncolytics Biotech (TSE ONC)

Source:
DateHeadline
Oncolytics Biotech (ONCYF) Updates On Clinical Data & Development Plan - SlideshowOncolytics Biotech (ONCYF) Updates On Clinical Data & Development Plan - Slideshow
seekingalpha.com - November 21 at 9:00 AM
BRIEF-Oncolytics Biotech Inc reports qtrly share of $0.02BRIEF-Oncolytics Biotech Inc reports qtrly share of $0.02
www.reuters.com - November 9 at 10:06 AM
Oncolytics Biotech® Appoints Deborah Brown to Board of Directors - PR Newswire (press release)Oncolytics Biotech® Appoints Deborah Brown to Board of Directors - PR Newswire (press release)
www.prnewswire.com - November 4 at 8:31 AM
Sorrento Therapeutics: Buy, Sell Or Hold After Its Big Rally?Sorrento Therapeutics: Buy, Sell Or Hold After Its Big Rally?
seekingalpha.com - October 14 at 6:26 AM
Form 6-K ONCOLYTICS BIOTECH INC For: Oct 11 - StreetInsider.comForm 6-K ONCOLYTICS BIOTECH INC For: Oct 11 - StreetInsider.com
www.streetinsider.com - October 13 at 7:44 AM
Oncolytics’ (ONCYF) End of Phase II MeetingOncolytics’ (ONCYF) End of Phase II Meeting
finance.yahoo.com - September 22 at 7:21 AM
BRIEF-Oncolytics announces successful end-of-Phase 2 meeting with FDA for reolysinBRIEF-Oncolytics announces successful end-of-Phase 2 meeting with FDA for reolysin
www.reuters.com - September 19 at 6:11 AM
BRIEF-Oncolytics Biotech announces first patient treated in Muk Eleven studyBRIEF-Oncolytics Biotech announces first patient treated in Muk Eleven study
www.reuters.com - September 14 at 8:46 AM
Oncolytics Biotech® Announces the Presentation of REOLYSIN ... - PR Newswire (press release)Oncolytics Biotech® Announces the Presentation of REOLYSIN ... - PR Newswire (press release)
www.prnewswire.com - September 12 at 8:40 AM
Oncolytics’ (ONCYF) Second Quarter ResultsOncolytics’ (ONCYF) Second Quarter Results
finance.yahoo.com - August 15 at 5:44 AM
FY2017 EPS Estimates for Oncolytics Biotech Inc. (ONC) Decreased by AnalystFY2017 EPS Estimates for Oncolytics Biotech Inc. (ONC) Decreased by Analyst
www.americanbankingnews.com - August 10 at 10:42 AM
Oncolytics Biotech® Inc. Announces 2017 Second Quarter ResultsOncolytics Biotech® Inc. Announces 2017 Second Quarter Results
finance.yahoo.com - August 4 at 6:40 AM
Oncolytics reports 2Q lossOncolytics reports 2Q loss
finance.yahoo.com - August 4 at 6:40 AM
Oncolytics Biotech® Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference - PR Newswire (press release)Oncolytics Biotech® Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference - PR Newswire (press release)
www.prnewswire.com - August 2 at 6:37 AM
BRIEF-Oncolytics Biotech granted end-of-phase 2 meeting with FDABRIEF-Oncolytics Biotech granted end-of-phase 2 meeting with FDA
www.reuters.com - July 27 at 6:04 AM
Oncolytics Biotech® to Present REOLYSIN® Safety Data in combination with chemotherapy at ESMO 2017 CongressOncolytics Biotech® to Present REOLYSIN® Safety Data in combination with chemotherapy at ESMO 2017 Congress
finance.yahoo.com - July 27 at 6:04 AM
Oncolytics (ONCYF) Raises CAD$11 MillionOncolytics (ONCYF) Raises CAD$11 Million
finance.yahoo.com - July 6 at 7:41 AM
Oncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of Oncolytics Biotech (US) Inc. - PR Newswire (press release)Oncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of Oncolytics Biotech (US) Inc. - PR Newswire (press release)
www.prnewswire.com - July 1 at 6:22 AM
Oncolytics Biotech® Inc. Opens US Based Office in San Diego - PR Newswire (press release)Oncolytics Biotech® Inc. Opens US Based Office in San Diego - PR Newswire (press release)
www.prnewswire.com - June 29 at 12:36 AM
Oncolytics Biotech® Prices Public Offering of UnitsOncolytics Biotech® Prices Public Offering of Units
www.prnewswire.com - May 24 at 7:16 PM
Oncolytics Biotech Prices Public Offering of UnitsOncolytics Biotech Prices Public Offering of Units
www.marketwatch.com - May 24 at 7:16 PM
BRIEF-Oncolytics Biotech prices public offering of unitsBRIEF-Oncolytics Biotech prices public offering of units
www.reuters.com - May 24 at 7:15 PM
FDA Grants Fast Track Status to Oncolytics Reolysin for Breast CancerFDA Grants Fast Track Status to Oncolytics' Reolysin for Breast Cancer
www.baystreet.ca - May 8 at 12:09 PM
BRIEF-Oncolytics Biotech Inc announces FDA fast track designation for ReolysinBRIEF-Oncolytics Biotech Inc announces FDA fast track designation for Reolysin
www.reuters.com - May 8 at 12:09 PM
Oncolytics Biotech® Inc. Announces Voting Results from its Annual Meeting of Shareholders - PR Newswire (press release)Oncolytics Biotech® Inc. Announces Voting Results from its Annual Meeting of Shareholders - PR Newswire (press release)
www.prnewswire.com - May 5 at 7:20 PM
Oncolytics Biotech® Inc. Announces 2017 First Quarter ResultsOncolytics Biotech® Inc. Announces 2017 First Quarter Results
www.prnewswire.com - May 5 at 8:53 AM
Oncolytics reports 1Q lossOncolytics reports 1Q loss
marketbeat.com - May 5 at 7:18 AM
Oncolytics Biotech announces registration pathway and clinical development plan - Seeking AlphaOncolytics Biotech announces registration pathway and clinical development plan - Seeking Alpha
seekingalpha.com - April 14 at 6:40 PM
Biopharmaceutical Market Scope Rising With Escalating Health Concerns - IndustryARCBiopharmaceutical Market Scope Rising With Escalating Health Concerns - IndustryARC
globenewswire.com - March 28 at 6:48 PM
BRIEF-Shanghai Shyndec Pharmas unit fined by food and drug authorities - ReutersBRIEF-Shanghai Shyndec Pharma's unit fined by food and drug authorities - Reuters
www.reuters.com - March 4 at 12:03 AM
Global Oncolytic Virus Landscape 2017: Key Players, Key Technologies, Projects, Business Deals and Private and ... - GlobeNewswire (press release)Global Oncolytic Virus Landscape 2017: Key Players, Key Technologies, Projects, Business Deals and Private and ... - GlobeNewswire (press release)
globenewswire.com - January 31 at 5:48 AM
Oncolytics Biotech® Inc. Appoints Dr. Matt Coffey to the Role of President and CEO - PR Newswire (press release)Oncolytics Biotech® Inc. Appoints Dr. Matt Coffey to the Role of President and CEO - PR Newswire (press release)
www.prnewswire.com - January 21 at 7:40 AM
BRIEF-Oncolytics Biotech names Matt Coffey CEOBRIEF-Oncolytics Biotech names Matt Coffey CEO
www.reuters.com - January 19 at 11:41 PM
Targovax announces appointment of Erik Digman Wiklund as CFO ... - GlobeNewswire (press release)Targovax announces appointment of Erik Digman Wiklund as CFO ... - GlobeNewswire (press release)
globenewswire.com - January 5 at 5:53 AM
Research Reports Initiated on Healthcare Stocks Immunovaccine, Oncolytics Biotech, and Theratechnologies - Baystreet.caResearch Reports Initiated on Healthcare Stocks Immunovaccine, Oncolytics Biotech, and Theratechnologies - Baystreet.ca
www.baystreet.ca - December 13 at 9:04 AM
Pioneers in Oncolytic Virus and Gene Therapy Fields Announce Formation of IGNITE Immunotherapy Inc., a Company ... - Business Wire (press release)Pioneers in Oncolytic Virus and Gene Therapy Fields Announce Formation of IGNITE Immunotherapy Inc., a Company ... - Business Wire (press release)
www.businesswire.com - December 12 at 7:09 PM

Social Media

Financials

Financials are not available for this stock.

Chart

Oncolytics Biotech (TSE ONC) Chart for Wednesday, November, 22, 2017
Loading chart…

This page was last updated on 11/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.